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The sera of 4 patients with bullous pemphigoid, of 5 
patients with drug reactions and of 13 patients with 
atopic eczema were examined for the occurrence of low 
molecular weight eosinophil chemotactic factor (ECF) 
by fractionation on a Sephadex G 25 column. Almost all 
patients had a peripheral eosinophilia, and many had 
raised total serum IgE levels. ECF was demonstrated in 
the sera of all 4 patients with bullous pemphigoid and in 
4 of 5 patients with systemic drug reactions. In contrast, 
the sera of the 13 patients with atopic eczema did not 
contain any ECF activity, nor did the 13 control sera. 
These findings suggest that the ECF from phagocytosing 
polymorphonuclear leukocytes (PMN) and/or the mast 
cell derived ECF-A contribute to the elevated serum ECF 
levels in patients with bullous pemphigo~d and drug 
reactions. A correlation between serum ECF and IgE 
levels and peripheral eosinophilia could not be estab-
lished. 
Eosinophil leukocytes are prominent participants in a wide 
variety of dermatological disorders. While their function is 
unknown, a number of factors have been described in recent 
years that induce the directed migration of these cells in vivo. 
These substances include the anaphylatoxin C5 a [1], a product 
of the prostaglandin series (HETE) [2], substances secreted by 
lymphocytes [3,4] and low molecular weight pep tides derived 
from mast cells (ECF-A) [5,6] and polymorphonuclear leuko-
cytes (ECF) [7,8]. The latter 2 factors are the most potent and 
selective eosinophil chemotactic factors known so far, and they 
cannot be differentiated from each other on a molecular weight 
basis. 
In the present study, the sera of patients with eosinophilia 
due to various dermatological diseases were screened for the 
presence of low molecular weight ECF-(A). Since this factor 
can be generated only by mast cells and peripheral polymor-
phonuclear (PMN) cells and not by macrophages and lympho-
cytes [9], the demonstration of ECF in sera during certain 
disease processes implicates the involvement of only either 
mast cells and/or PMN in the inflammatory reaction. This 
fmding gives, in turn, an indication of the types of nonspecific 
and specific immune mechanisms involved in dermatoses with 
associated eosinophilia. 
MATERIALS AND METHODS 
Blood was obtained by venipuncture from patients with various 
dermatological diseases associated with eosinophilia and from normal 
controls. After clotting for 1 hr at 21°C and for an additional 1 hr at 
4°C, the blood was centrifuged at 2,500 g for 30 min at 4°C and stored 
at -60°C or subjected to examination immediately. 
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For column chromatography, 200 ~tl of patient or control sera were 
applied to a Sephadex G 25 medium (Pharmacia, Uppsala, Sweden) 
column (14 x 1.2 em) and eluted in Tris buffer (pH 7.35, 0.025 M). ECF-
A from sonicated rat mast cells or human lung fragments and ECF 
obtained after phagocytosis of zymosan by human PMN [8] served as 
markers for ECF activity. Blue dextran 2,000 (Pharmacia, Uppsala, 
Sweden), vitamin B I " (Sigma Chemical Co., St. Louis, Mo.) and phenol 
red were used similarly as molecular markers. Fractions of 700 /11 each 
were collected, diluted to a final volume of 1.2 ml in Tris buffer 
supplemented with calcium (0.6 mM), magnesium (l.0 mM) and human 
albumin (0.3 mg/ ml) and tested in the chemotaxis assay. Each serum 
was eluted on at least 2 separate occasions. 
The eosinophil chemotaxis assay has been described previously in 
detail [7,9]. Briefly, 2.5 X 101; guinea pig peritoneal exudate cells or 
human peripheral leukocytes containing at least 20% eosinophils were 
placed on a nitrocellulose fllter (Sartorius Membran Filter GmbH, 
Giittingen, W. Germany) and the test substance in a total of 1.2 ml 
below the fi.lter in plexiglass Boyden chemotaxis chambers. After an 
incubation of 3 hr at 37°C and 100% humidity, the filters were removed, 
stained and mounted on glass slides. Eosinophils that had migrated 
completely through the filter in 5 random high power fields were 
counted under 450 x magnification, With each chemotaxis, the activity 
of 100 /11 of the sera alone, of the sera plus ECF (l00 Ill, PMN-derived) 
and of ECF alone was tested. Alternate column fractions were examined 
during different chemotaxis experiments to ensure duplicability of the 
resu lts. 
Serum IgE was measured with the Phadebas Radioimmun'e-Test 
(Pharmacia, Uppsala, Sweden). 
RESULTS 
The upper part of the Fig shows a typical elution curve for 
PMN-derived ECF. This picture is very similar to the elution 
pattern described previously with larger size columns [7,9]. The 
peak ECF-activity ranges between a molecular weight of 1,335 
(vitamin B 12) and 364 (phenol red), and the same elution pattern 
is observed with mast cell derived ECF-A. 
In the center and at the bottom of the Fig, the elution curves 
of serum from a patient with bullous pemphigoid and that of a 
patient with atopic dermatitis each is shown. Although the ECF 
activity is not as high as that of the neutrophil-derived ECF 
(and this was consistently so when serum activity was compared 
with ECF prepared in vitro), there is clear evidence for ECF 
activity in the bullous pemphigoid serum, while the serum from 
the patient with atopic dermatitis does not show this peak. 
The data from. 4 patients with bullous pemphigoid are sum-
marized in Table I. Clinically, all these patients had a typical 
picture of this disease, with large, subepidermal bullae and a 
positive indirect IgG immunofluorescence pattern at the base-
ment membrane. In each case, ECF, as illustrated in Fig 1, was 
found. The IgE levels were elevated in only 3 of the patients, 
and there was a marked eosinophilia in all of them except for 
the one case where the differential leukocyte count was not 
available. 
The sera of 5 patients with systemic drug reaction and skin 
rashes were similary examined . Four of them had an elevated 
IgE level, and the percentage of eosinophils was increased in 
almost all cases. ECF was found in the sera from 4 of the 5 
patients (Table II) . 
In contrast to these findings, the sera of 13 patients with 
atopic eczema were negative for ECF in each case. The disease 
of all these patients was severe enough to require hospitaliza-
tion. Eight were children, and none of the patients received 
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FIG 1. Elution pattern of test substances on a Sephadex G 25 M 
column. Blue dextran (D.El.), vitamin B " and phenol red are used as 
molecular markers. Eosinophil chemotactic activity is expressed as the 
number of eosinophils that have migrated completely through the filter 
in 5 high power microscopic fields (5 HPF). The upper portion shows 
t he elution pattern for PMN-derived ECF which has very high activity 
compared to that of serum from a patient with bullous pemphigoid in 
the center. Note different scales! No eosinophil chemotactic factor 
(ECF) is found in the serum of a patient with atopic eczema. The 
findings ar e representative for the ECF elevation in patients with 
bullous pemphigoid and drug reactions on the one hand and the lack of 
ECF in patients with atopic eczema a nd controls on the other hand. 
steroids, topically or systemically. As shown in Table III, the 
mean IgE level of this group was markedly elevated compared 
to the other 2 patient groups. All patients had an eosinophilia. 
Table III summarizes the results of the 3 patient groups and 
the controls. The elevated ECF level in patients with bullous 
pemphigoid and drug reactions stands in striking contrast to 
the negative findings in the patients with atopic eczema and 
the controls. There is no relationship between serum IgE levels, 
eosinophilia and occurrence of ECF in serum. 
Since the lack of ECF activity might be due to an elevated 
level of inhibitors [10] in atopic or control sera, all sera were 
tested against a standard ECF preparation in the chemotaxis 
assay. The inhibition by serum was dependent only on the 
activity of the ECF standard. Thus, as we have reported pre-
viously, all the sera were inhibitory during very active eosino-
phil chemotaxis (> 200 Eos/5 HPF) and caused synergistically 
enhanced migration with low ECF stimulation [11). 
Quantitative differences in this behavior between the differ-
ent patient groups and the controls were not observed. 
Vol. 73, No . 2 
TABLE 1. Eosinophilic chemotactic fa ctor in bullous pemphigoid" 
Patient ECF" IgE (U / ml) % Eosinophils 
H.L. 
M .R. 
U.W. 
A.H. 
+ 
+ 
+ 
+ 
300 
70 
1200 
150 
23 
30 
nd" 
28 
" Summary of occurrence of serum ECF (+), of serum IgE levels and 
of t he percentage of peripheral eosinophils in the 4 patients with 
bullous pemphigoid. 
II ECF = eosinophil chemotactic factor. 
'.' nd = not done. 
TABLE n. ECF in drug reactions" 
Pat. ient Cause of ECF" IgE drug reac tion (U j ml) 
H.K. Sulfonamides 800 
A.T. Buphenin? + 80 
1.W. Salicylates + 220 
A.G. Bactrim + 340 
M.F. Salicylates + 600 
(Lyell -syndrome) 
% 
Eosinophils 
17 
14 
13 
16 
5 
" Occurrence of serum ECF, IgE levels and percentage of peripheral 
eosinophils in 5 patients with systemic drug reactions of various causes. 
II ECF = eosinophil chemotactic factor. 
TABLE III . Comparison of the frequency of elevated serum ECF, of 
mean serum JgE and the mean percentage of peripheral eosinophils 
in the three patient and the control groups 
No. pa-
mean se· mean % Total No. tients with Diagnosis patients serum rum IgE Eosino-
ECF" (U/ ml) phils 
Bullous pemphigoid 4 4 430 27 
Drug reaction 5 4 408 13 
Atopic eczema 13 1467 18 
Controls 13 65 5 
" ECF = eosinophil chemotactic factor. 
DISCUSSION 
These data demonstrate clem' differences in the occurrence 
of low molecular weight ECF among patient groups that resem-
ble each other by the association of blood eosinophilia and 
elevated mean serum IgE levels. Since the groups do not differ 
with regard to inhibitors or enhancing factors in the serum, one 
must assume that the ECF in the serum of patients with bullous 
pemphigoid and drug reactions is present in excess due to active 
secretion by mast cells and/or ·PMN. 
So far, serum ECF activity has been reported only once in 
the venous effluent of patients with cold urticaria after local 
challenge [12]. Since a simultaneous rise in serum histamine 
was observed, it is reasonable to believe that the cell source of 
the 2 mediators was the mast cell. Low molecular weight ECF 
has also been found in blister fluid of patients with bullous 
pemphigoid [13], and degranulated mast cells have been local-
ized in the nearby tissue [14]. This secretion of mediators from 
mast cells could be induced by IgE mediated mechanisms or by 
the locally generated anaphylatoxins in bullous pemphigoid 
lesions [15]. The latter factors are also chemotactic for eosino-
phils and neutrophils, while other products of complement 
activation are available to enhance the phagocytosis of immune 
complexes at the basement membrane. This leads to the gen-
eration of ECF from neutrophils and eosinophils. A complex 
interaction between complement, mast cells and PMN can thus 
occur, leading to optimal eosinophil chemotactic activity in 
bullous pemphigoid lesions. 
Such a cumulative effect of ECF generation induced by 
several mechanisms might also occur during drug reactions 
where one finds elevated IgE levels, immune complexes and 
activation of the complement cascade. 
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In atopic dermatitis, IgE levels are markedly elevated and 
C5a has been demonstrated in the serum (16). The distinguish-
ing feature of this disease is the relative paucity of participation 
by neutrophils and the more prominent role of mononuclear 
leukocytes in the local inflammatory reaction. We have previ-
ously shown that the latter cells contain potent inhibitors for 
ECF, exceeding on a quantitative basis the inhibitory activity 
in neutrophils [17]. This might be one reason for the lack of 
ECF in the serum. In addition, if indeed ECF-A was released 
by mast cells, the quantity might be too small or the half-life of 
t he factor in serum too short to be detected by our methods. 
The peak serum ECF-A level after cold challenge in urticaria, 
as reported in the literature [12], reached the relatively large 
amount of ECF found in the serum of our patients with bullous 
pemphigoid only in 1 of 3 cases, and then only 5 min after cold 
challenge. The quantity of ECF-A in mast cells alone might 
thus not suffice to cause the marked elevation of ECF in serum 
observed among the patients with bullous pemphigoid and drug 
reactions. 
Baba et al [13] fa iled to observe eosinophil chemotactic 
activity in serum of patients with bullous pemphigoid. This 
might be due to the much higher levels of ECF in blister fluid, 
compared to serum, reported by us elsewhere [18]. Differences 
in handling of t he serum or in the sensitivity of the assay system 
might explain their negative results. 
Testing of whole serum without fractionation leads to very 
fallacious results in our hands because of the marked modulat-
ing effect of various serum components on migrating cells and 
on ECF. For this reason, we elected not to evaluate the eosin-
ophil chemotactic activity in the G 25 void volume since it 
would be a composite of the serum modulating factors [10,11] 
as well as a mixtme of higher molecular weight eosinophil 
ch emotactic factors such as C5a [1], the lymphokines [3,4] or 
t he higher molecular weight eosinophil chemotactic products 
of mast cells [19] a nd neutrophils [7,9]. Differentiation of all of 
t hese factors was beyond the scope of this study. 
It would, however, be desirable to be able to distinguish 
whether the low molecular weight ECF from mast cells or from 
polymorphonuclear leukocytes was the source of ECF activity 
in the different disease groups. We have been able to show 
differences in the way the 2 cell types handle the factor [20], 
but unfortunately not in biological, molecular weight or electro-
phoretic properties of the various ECFs [7,9,20,21]' 
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in its generation. Furthermore, this study suggests that several 
chemotactic factors interact to cause the final accumulation of 
eosinophils at sites of inflammatory reactions. 
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The ECF-A in mast cells is partially preformed and stored 
together with histamine in larger granules, while the ECF in 
basophils and neutrophils is generated only after stimulation 
and is then found in a very light granule fraction [20]. This 
might be one possible way to establish the source of ECF. 
Therefore, we have sonicated peripheral leukocytes of some of 
t he patients reported in this study and were able to demonstrate 
indeed elevated levels of ECF in the cells from subjects of all 3 
patient groups, compared to controls. However, since both IgE 
mediated mechanisms (basophils) and phagocytosis by neutro-
phils could have generated ECF in these peripheral leukocytes, 
these findings were, again, not helpful in elucidating the som ce 
of the elevated serum ECF. 
In summary, while definite proof for the cell source of serum 
ECF is missing, the lack of this factor in atopic dermatitis and 2l. 
its transient elevation during anaphylactic challenge implicates 
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